Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$8.7MCash on Hand
5.8mo Cash Runway
Follow PLUR by emailGet an email when PLUR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PLUR, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 30, 2026 ·
Deal Pluri entered a partnership agreement with ZEO ScientifiX granting ZEO an exclusive U.S. license to manufacture and commercialize its regenerative medicine products, excluding aesthetics, skin care, cosmetic and veterinary uses. Form 8-K · SEC filing
Oct 20, 2026 ·
Financing Pluri agreed to sell 833,334 common shares at $1.50 each plus a warrant for 833,334 shares at $1.65 to Chutzpah Holdings LP, a vehicle of chairman and largest shareholder Alexandre Weinstein. The $1,250,000 he advanced in June is applied in full to the price, and no further payment is due at closing. Form 8-K · SEC filing
Oct 6, 2026 ·
Financing Pluri registered up to 2,228,940 common shares issuable on warrant exercises for a selling shareholder, with the stock at $1.04 on October 5, 2026. Warrants at $1.65 would bring about $3,677,751 to the company if all are exercised for cash. Form S-1 · SEC filing
Sep 11, 2026 ·
Financing Pluri Inc. filed a shelf registration statement to sell common shares, preferred stock, warrants and units for an aggregate initial offering price of $200,000,000, with terms to be set in later prospectus supplements. The last reported sale price of its common shares on Nasdaq was $1.37. Form S-3 · SEC filing
Sep 10, 2026 ·
Annual report for the period ended Jun 30, 2026 Form 10-K · SEC filing
Aug 28, 2026 ·
Financing Pluri agreed to sell 1,200,000 common shares at $1.50 plus pre-funded warrants for 1,028,940 shares in a registered direct offering, with common warrants for 2,228,940 shares at $1.65. Expected net proceeds are about $2,984,808, closing August 28, 2026. Form 8-K · SEC filing
Aug 28, 2026 ·
Financing Pluri is selling 1,200,000 common shares plus pre-funded warrants for up to 1,028,940 shares at $1.50 per share, with a concurrent private placement of warrants for up to 2,228,940 shares at $1.65. Gross proceeds total $3,343,400 before a $217,322 placement fee. Form 424B5 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
PLUR holds $8.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $4.5M/quarter from operations,
an estimated runway of 5.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:90 · High
Cash runway 6 months +40
ATM program on file since Feb 2024 +15
Shelf registration (S-3, Sep 2026) +10
Going-concern doubt in the latest 10-Q +15These conditions raise substantial doubt about the Company’s ability to continue as a going concern.10-Q, Nov 2026
Share count +55% in a year +20
Raised after last reported balance sheet (Oct 2026) -10
Share count 14,375,922 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full PLUR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PLUR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.